PRINCETON, N.J. — Dr. Reddy’s Laboratories and its subsidiary, Promius Pharma. today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute treatment of migraine with or without aura in adults. Tosymra is the latest product to join the Promius Pharma acute migraine treatment
PRINCETON, N.J. — Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, has unveiled its new visual identity and corporate brand: The Power of Humans Being. The initiative is designed to express the core belief at Promius Pharma that “every patient is a person first” and its mission to “help patients get back to what
PRINCETON, N.J. — Promius Pharma LLC has received Food and Drug Administration approval for Sernivo Spray 0.05%, a psoriasis medication. A prescription topical steroid, Sernivo Spray (betamethasone dipropionate 0.05%) is indicated for the treatment of mild to moderate plaque psoriasis in adult patients, according to Promius, the U.S. subsidiary of India-based Dr. Reddy’s Laboratories. “The
